GeneDx Holdings

WGS

Market cap $3.16B

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of GeneDx Holdings Corp. (NASDAQ: WGS) breached their fiduciary duties to shareholders. If you currently own GeneDx stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your le.

GeneDx Holdings Corp. (WGS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

GeneDx Holdings Corp. is positioned as a leader in advanced exome and genome diagnostics, leveraging its expanding rare disease dataset. Fourth quarter preliminary results met guidance but did not exceed it sufficiently for a high multiple stock, resulting in a pullback. Company's 2026 guidance was strong and above expectations with testing volume growth of 33-35%.

GeneDx stock (NASDAQ: WGS) plunged 14% on Monday after the genomics testing company released preliminary full-year 2025 results that met expectations. But the company unveiled 2026 guidance that investors deemed disappointingly conservative, wiping out significant gains and reigniting concerns about the high-growth biotech's ability to maintain breakneck expansion.

WGS collaborates with Komodo Health to link genomic data with real-world insights, expanding data monetization and strengthening its role in rare disease research.

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx reported high growth and profitability in preliminary results for the fourth quarter and full year of 2025 and issued 2026 guidance.

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Komodo Health Partner to Build the World's Most Complete Longitudinal Rare Disease Dataset.

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx announced GenomeDx Prenatal™, a whole genome sequencing test that delivers fast, comprehensive insights when fetal anomalies are identified.

GAITHERSBURG, Md.--(BUSINESS WIRE)--Dr. Linda Genen named CMO to further strengthen GeneDx's commitment to delivering earlier answers and better outcomes through genomic insights.

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx announced a record-setting year for its research programs, reinforcing its position as the global leader in rare disease genomics.